Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke

 

Algernon Pharmaceuticals Inc. CEO Christopher J. Moreau and guest Dr. David Nutt, renowned neuropsychopharmacologist and DMT consultant discuss the Company’s upcoming Phase 1 study of DMT for Stroke.

Live Interview – July 8, 2021

Share via
Copy link
Powered by Social Snap